Amines were reacted with lactones 7 or with unsaturated nitro derivatives 8 to give isoindole and pyrazino[2,1-a]isoindole derivatives. The mechanisms of formation, proofs of structure, and stereochemistry are presented.
Etodolac, 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid, a clinically effective analgesic and antiinflammatory agent, has been resolved via a chromatographic separation of its diastereoisomeric esters with (-)-borneol. The effects of the enantiomers were studied in vitro on prostaglandin synthetase and on adjuvant-induced arthritis in rats. The biochemical and pharmacological results show that virtually all of the effects of etodolac are due to the (+) enantiomer.
A series of 37 1-ethyl- and 1-n-propyl-1, 3, 4, 9-tetrahydropyrano[3, 4-b]indole-1-acetic acids bearing one, or two, substituents on the benzene ring has been synthesized via the acid-catalyzed condensation of a substituted tryptophol with ethyl propionylacetate or ethyl butyrylacetate. Antiinflammatory and ulcerogenic effects were examined and the results show that 1, 8-diethyl-1, 3, 4, 9-tetrahydropyrano[3, 4-b]indole-1-acetic acid (etodolic acid, USAN) is a potent agent, particularly active against a chronic rat model of inflammation (ED50 0.7 + 1-0.1 mg/kg po in the adjuvant arthritis model) and which has a relatively low acute ulcerogenic potential in the same species.
Four human subjects were given a capsule containing 200 mg of 14C-etodolac. At the peak (two hours after dosing), most of the radioactivity in serum was due to etodolac; subsequently, metabolites gradually appeared. The elimination half-life of etodolac from serum averaged six hours. Etodolac was greater than 99% bound to human serum proteins. An average of 73% of the dose was excreted in the urine and 14% in faeces within seven days, with 61% appearing in the urine during the first 24 h. Microbial transformation of etodolac was employed to biosynthesize sufficient amounts of two urinary metabolites to facilitate structure elucidation. Five metabolites, representing 65% of the radioactivity in urine collected 0-24 h after dosing (61% of the dose was excreted in urine within 24 h), were isolated and characterized by t.l.c., g.c., h.p.l.c., n.m.r (1H and 13C) and m.s. Most of the identified urinary components were conjugates of etodolac and three hydroxylated metabolites (6-hydroxyetodolac, 7-hydroxyetodolac and 8-(1-hydroxyethyl)etodolac). Two metabolites were identified as glucuronyl ester conjugates of etodolac and 7-hydroxyetodolac; the former represented about 20% of the urinary radioactivity. False positive tests for bilirubin in urine of patients treated with etodolac were found to be due to the two phenolic metabolites.
A series of 3,4-dihydro-1H-1,4-oxazino[4,3-a]indoles bearing basic side chains has been synthesized by a novel chemical process. These compounds have been screened for potential antidepressant activity. One of these derivatives, 3,4-dihydro-1,10-dimethyl-1-(3-methylaminopropyl)-1H-1,4-oxazino[4,3-a]indole (AY-23,673), was particularly potent in the prevention of reserpine ptosis test in mice, with an ED50 of 0.5 mg/kg ip.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.